Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Revamps U.S. Pharma Unit, With New CEO Andre Wyss

Executive Summary

Novartis is reorganizing its U.S. pharmaceutical business, effective May 1, a move that includes the departure of Ludwig Hanston, who ran the unit for the past two years, and the elimination of nearly 400 positions mostly at U.S. headquarters, the company's Global Pharma CEO David Epstein told employees in a memo distributed on April 13
Advertisement

Related Content

Novartis Sales Rise 25%; Jimenez Talks Up U.S. Commercial Restructuring In Interview
Novartis' Gilenia Extension Trial Data Support Efficacy Of Low-Dose Version
Novartis Splits Chair and CEO Positions, Names Joe Jimenez CEO
No Sales Model Left Behind: Novartis Joins Firms In Changing Market Focus
No Sales Model Left Behind: Novartis Joins Firms In Changing Market Focus

Topics

Advertisement
UsernamePublicRestriction

Register

PS052142

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel